Andrew D. Zelenetz, MD, PhD

Andrew D. Zelenetz, MD, PhD

Areas of Expertise

Conditions I Treat

  • Hodgkin lymphoma (Hodgkin’s disease)
  • Non-Hodgkin lymphoma (NHL)
  • Small lymphocytic lymphoma (SLL)

My Specialties

  • Immunotherapy
Request an Appointment
Our Care Advisors can answer many of your questions. They will connect you with the best healthcare provider for your needs.

Get to Know Me

I am a medical oncologist with special expertise in lymphoma, and former Chief of Memorial Sloan Kettering’s Lymphoma Service. I am a member of a close-knit team that provides compassionate, multidisciplinary care to patients with lymphoma.

I have helped develop a number of the agents now approved to treat lymphoma — including 131I-tosituomab/tositumomab, bortezomib, and pralatrexate — and through clinical studies I am evaluating the benefits of novel combinations of agents. In another area of research I am working to improve the prognostic value of patients’ pathology specimens using computer-aided image analysis. I have published more than 100 papers on lymphoma research in journals such as Blood, Journal of Clinical Oncology, and Clinical Cancer Research.

I am involved in several national organizations that provide information about lymphoma treatment and fund laboratory and clinical research. I am chairperson of the Non-Hodgkin Lymphoma Guidelines panel of the National Comprehensive Cancer Network and vice chairperson of the Lymphoma Core Committee of the Cancer and Leukemia Group B. I am also a member of the scientific advisory board of the Lymphoma Research Foundation.

What I Do at MSK

I'm a lymphoma specialist, which is a doctor with special training in diagnosing and treating lymphoma (lim-FOH-muh). This cancer starts in the cells of the immune system.

  • Medical Director, Quality Informatics
Areas of Expertise

Conditions I Treat

  • Hodgkin lymphoma (Hodgkin’s disease)
  • Non-Hodgkin lymphoma (NHL)
  • Small lymphocytic lymphoma (SLL)
  • Diffuse large b-cell lymphoma (DLBCL)
  • Mantle cell lymphoma (MCL)
  • Chronic lymphocytic leukemia (CLL)
  • Lymphoma

My Specialties

  • Immunotherapy
Education & Honors

Education

  • MD, Harvard Medical School

Residencies

  • Medicine - Stanford University Medical Center

Fellowships

  • Oncology - Stanford University Medical Center

Board Certifications

  • Internal Medicine
  • Medical Oncology

Awards and Honors

  • Castle Connolly: America’s Top Doctor (2025)
  • Castle Connolly: America’s Top Doctor (2024)
  • Top Doctors New York Metro Area, Castle Connolly (2023)
  • Castle Connolly: America's Top Doctors (2016-2021, 2023)
  • Castle Connolly: New York Magazine Top Doctors (2002-2022)

Insurance Information

Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.

Don't see your carrier or plan? We can help you understand your coverage.

If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.

If you have questions about insurance, call us at 646-497-9176.

Make an Appointment

Current Patients
Request an appointment by calling your Care Team or messaging them in MSK MyChart.

Contact and Location

Office Phone
Location
New York, NY

Looking to see a doctor at a different location? See all MSK locations.

Colleagues

Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.

See all Medicine doctors

See all Lymphoma Service doctors

Clinical Trials

Research and Publications

Publications on PubMed

Visit PubMed for a full listing of Dr. Zelenetz’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.

See all on PubMed

Disclosures

Members of the MSK Community often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community. These activities outside of MSK further our mission, provide productive collaborations, and promote the practical application of scientific discoveries.

MSK requires doctors, faculty members, and leaders to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public. Not all disclosed interests and relationships present conflicts of interest. MSK reviews all disclosed interests and relationships to assess whether a conflict of interest exists and whether formal COI management is needed.

Andrew D. Zelenetz discloses the following relationships and financial interests:

  • AbbVie
    Professional Services and Activities
  • Allogene Therapeutics
    Professional Services and Activities
  • AstraZeneca
    Professional Services and Activities
  • BeiGene USA, Inc.
    Professional Services and Activities
  • Curio Science LLC
    Professional Services and Activities
  • Dava Oncology
    Professional Services and Activities
  • Eli Lilly and Company
    Professional Services and Activities
  • Genentech
    Professional Services and Activities
  • GenMab
    Professional Services and Activities
  • Ipsen Pharma
    Professional Services and Activities
  • Kite Pharmaceuticals
    Professional Services and Activities
  • Ono Pharma
    Professional Services and Activities

If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.

The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.


This page and data include information for a specific MSK annual disclosure period (January 1, 2024 through disclosure submission in spring 2025). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures